Mechanisms of cancer drug resistance

Annual Review of Medicine

Volumn 53, Issue , 2002, Pages 615-627

  Gottesman, Michael M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

ABC transporters; Cancer; Chemotherapy; Drug transport; Multidrug resistance

Indexed keywords

ABC TRANSPORTER; ANTHRACYCLINE DERIVATIVE; ANTIARRHYTHMIC AGENT; ANTIHISTAMINIC AGENT; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; ARSENIC ACID; ARSENIC TRIOXIDE; BIRICODAR; CADMIUM; CHLORMETHINE; CISPLATIN; DAUNORUBICIN; DEXNIGULDIPINE; DEXVERAPAMIL; DOXORUBICIN; FOLIC ACID ANTAGONIST; GLYCOPROTEIN P; MERCURY; METHOTREXATE; MITOXANTRONE; PACLITAXEL; PROTEINASE INHIBITOR; STATINE DERIVATIVE; UNINDEXED DRUG; VALSPODAR; VINBLASTINE; VINCA ALKALOID; VINCRISTINE; ZOSUQUIDAR;

APOPTOSIS; CANCER; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CELL COMPARTMENTALIZATION; DRUG DETOXIFICATION; DRUG METABOLISM; DRUG TARGETING; DRUG TRANSPORT; DRUG UPTAKE; HUMAN; LIPID MEMBRANE; MULTIDRUG RESISTANCE; NONHUMAN; PHARMACOGENETICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL SURVIVAL; DRUG RESISTANCE, NEOPLASM; HUMANS; METABOLIC DETOXICATION, DRUG; NEOPLASMS;

EID: 0036176510     PISSN: 00664219     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.med.53.082901.103929     Document Type: Review

References (62)

1. From bench top to bedside
2. New adjuvant strategies for breast cancer: Meeting the challenge of integrating chemotherapy and trastuzumab (Herceptin)
3. Immunotoxins for targeted cancer therapy
4. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome
5. Role of tumor-host interactions in interstitial diffusion of macromolecules: Cranial vs. subcutaneous tumors
6. Adhesion-dependent multicellular drug resistance
7. Current understanding of methotrexate pharmacology and efficacy in acute leukemias. Use of newer antifolates in clinical trials
8. Exploiting multidrug resistance to treat cancer
9. Ceramide glycosylation potentiates cellular multidrug resistance
10. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents
11. The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux
12. Lung resistance-related protein: Determining its role in multidrug resistance
13. A family of drug transporters: The multidrug resistance-associated proteins
14. Biochemical, cellular and pharmacological aspects of the multidrug transporter
15. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants
16. Expression of a full-length cDNA for the human MDR1 gene confers resistance to colchicine, doxorubicin, and vinblastine
17. Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells
18. The three mouse multidrug resistance (mdr) genes are expressed in a tissue-specific manner in normal mouse tissues
19. Alternate overexpression of two P-glycoprotein genes is associated with changes in multidrug resistance in a J774.2 cell line
20. ABC transporters: From microorganisms to man
21. Expression of a multidrug resistance gene in human cancers
22. Mutations in the MDR3 gene cause progressive familial intrahepatic cholestasis
23. HMG-CoA reductase inhibitors and P-glycoprotein modulation
24. HIV-1 protease inhibitors and the MDR 1 multidrug transporter
25. Human P-glycoprotein exhibits reduced affinity for substrates during a catalytic transition state
26. Evidence for a requirement for ATP hydrolysis at two distinct steps during a single turnover of the catalytic cycle of human P-glycoprotein
27. Characterization of the catalytic cycle of ATP hydrolysis by human P-glycoprotein
28. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line
29. Characterization of MOAT-C and MOAT-D new members of the MRP/cMOAT subfamily of transporter proteins
30. r 190,000 multidrug resistance protein (MRP): Evidence for cotransport with reduced glutathione
31. The multidrug resistance protein family
32. MRP3, an organic anion transporter able to transport anti-cancer drugs
33. Multidrug-resistance protein 5 is a multispecific organic anion transporter able to transport nucleotide analogs
34. A multidrug resistance transporter from human MCF-7 breast cancer cells
35. A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance
36. Molecular cloning of cDNAs which is highly overexpressed in mitoxantrone-resistant cells: Demonstration of homology to ABC transport genes
37. Identification of breast cancer resistant protein/mitoxantrone resistance protein/placenta-specific. ATP-binding cassette transporter as a transporter of NB-506 and J-107088, topoisomerase I inhibitors with an indolocarbazole structure
38. ABC transporters in lipid transport
39. Taxol resistance mediated by transfection of the liver-specific sister gene of P-glycoprotein
40. Amplification of the ATP-binding cassette 2 transporter gene is functionally linked with enhanced efflux of estramustine in ovarian carcinoma cells
41. Cellular accumulation of the anticancer agent cisplatin: A review
42. Cross-resistance to methotrexate and metals in human cisplatin-resistant cell lines results from a pleiotropic defect in accumulation of these compounds associated with reduced plasma membrane binding proteins
43. Decreased accumulation of [14C]-carboplatin in human cisplatin-resistant cells results from reduced energy-dependent uptake
44. Genetic polymorphism in MDRI: A tool for examining allelic expression in normal cells, unselected and drug-selected cell lines, and human tumors
45. Rapid activation of MDR1 gene expression in human metastatic sarcoma after in vivo exposure to doxorubicin
46. Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia
47. Cyclosporine A as a modifier agent in the salvage treatment of acute leukemia (AL)
48. P-glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma
49. Clinical relevance of transmembrane drug efflux as a mechanism of multidrug resistance
50. Treatment of refractory and relapsed acute myelogenous leukemia with combination chemotherapy plus the multidrug resistance modulator PSC833 (Valspodar)
51. Novel technetium (III)-Q complexes for functional imaging of multidrug resistance (MDR1) P-glycoprotein
52. Normal viability and altered pharmacokinetics in mice lacking mdrl-type (drug-transporting) P-glycoproteins
53. Extensive contribution of the multidrug transporter P-glycoprotein and mrp1 to basal drug resistance
54. The pharmacological phenotype of combined multidrug-resistance mdrl a/1 b- and mrpl-deficient mice
55. Transport of opioids from the brain to the periphery by P-glycoprotein: Peripheral actions of central drugs
56. Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo
57. Genetic analysis of the multidrug transporter
58. Selectable markers for gene therapy
59. Retroviral transfer of the human MDR1 gene permits selection of drug resistant bone marrow cells in vivo
60. Engraftment of MDR1 and NeoR gene-transduced hematopoietic cells after breast cancer chemotherapy
61. Transduction of murine bone marrow cells with an MDR1 vector enables ex vivo stem cell expansion, but these expanded grafts cause a myeloproliferative syndrome in transplanted mice